Application of chimeric antigen receptor T cell targeting NKG2D in treatment of prostate cancer, and medicine for treating prostate cancer

Abstract

The invention provides an application of a chimeric antigen receptor T cell targeting NKG2D in preparation of a medicine for treating prostatic cancer. Compared with an existing clinical prostate cancer treatment technology, the chimeric antigen receptor T cell targeting NKG2D is high in proliferation speed, high in activity and long in half-life period in a human body, can exert a capacity of efficiently and specifically killing prostate cancer cells in a long-acting and lasting mode, and has a good treatment effect on prostate cancer. The invention also provides a medicine for treating prostatic cancer.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of a chimeric antigen receptor T cell targeting NKG2D in the preparation of a drug for treating prostate cancer, and the drug for treating prostate cancer. Background technique [0002] Prostate cancer is the second most common cancer in men worldwide and the fifth leading cause of cancer-related death in men. Traditional radiotherapy and chemotherapy methods have relatively large toxic and side effects on prostate cancer patients, and prostate cancer is prone to recurrence and metastasis. Although several new drugs have been approved recently for the treatment of metastatic hormone-resistant prostate cancer, such as abiraterone acetate, enzalutamide, and cabazitaxel, these drugs only prolong the life of patients by a few months. In addition, tumor immunotherapy has also become a hot spot in the field of oncology. Some tumor immunotherapy has also shown certain effects...

AI Technical Summary

Problems solved by technology

Although NKG2D ligands provide a more precise target for tumor immunotherapy, the current research on the application of C

Images